Candel Therapeutics executed two financing transactions that could generate up to $200 million to support commercialization of CAN‑2409 (aglatimagene besadenovec), its intraprostatic adenoviral‑based immunotherapy for localized prostate cancer. The company priced a $100 million equity offering and arranged a conditional $100 million royalty financing with RTW Investments contingent on FDA approval. Candel emphasized that the proceeds extend runway into expected approval and launch timing, and the royalty deal ties payments to US net sales with a capped total. The financing package highlights investor appetite for late‑stage cell and gene therapy assets with clear near‑term regulatory catalysts.